Amgen wins latest round in high-stakes patent showdown

26 February 2019

On Monday, another chapter in the years-long legal saga between Amgen (Nasdaq: AMGN) and Sanofi (Euronext: SAN) was written by a District Court jury, which upheld certain patents for Amgen’s Repatha (evolocumab).

Billions of dollars in potential revenue are up for grabs, as the firms’ competing cholesterol busters battle it out. Both companies have also aggressively cut prices in recent months in an attempt to grow market share.

The court in Delaware found that three of five asserted claims for patents covering the PCSK9 blocker were valid, a decision which caused shares in Sanofi and its US-based development partner Regeneron (Nasdaq: REGN) to tick downwards.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK